BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

MiMedx (MDXG)MiMedxEarnings

Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL ® Regulatory Classification Matter During Quarter Today Announced Patent License

Related news

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MDXGMiMedx2026-07-29 20:07 EST

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

ADMAADMA Biologics2026-11-04 21:05 EST

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

STTKShattuck Labs2026-08-11 10:15 EST

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

APGEApogee Therapeutics2026-08-10 11:00 EST

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

ENTXEntera Bio2026-08-07 20:05 EST

Entera Announces Second Quarter 2026 Financial Results and Business Updates

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-11-06 13:00 EST

MIMEDX to Participate in Upcoming Investor Conferences

MDXGMiMedx2026-10-28 20:03 EST

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-10-28 20:01 EST

MIMEDX Announces $25 Million Patent License Agreement

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MDXGMiMedx2026-09-23 20:01 EST

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Stock data

Close
3.28 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States